This article was downloaded by: [New York University] On: 19 February 2015, At: 06:28 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK Virulence Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/kvir20 Hpv and cancer of the oral cavity a b Christian U. Hübbers & Baki Akgül a Jean-Uhrmacher-Institute for Otorhinolaryngological Research, University of Cologne, Geibelstr. 29, 50931 Cologne, Germany; b Institute of Virology, University of Cologne, Fürst-Pückler-Str. 56, 50935 Cologne, Germany Accepted author version posted online: 05 Feb 2015. Click for updates To cite this article: Christian U. Hübbers & Baki Akgül (2015): Hpv and cancer of the oral cavity, Virulence To link to this article: http://dx.doi.org/10.1080/21505594.2014.999570 Disclaimer: This is a version of an unedited manuscript that has been accepted for publication. As a service to authors and researchers we are providing this version of the accepted manuscript (AM). Copyediting, typesetting, and review of the resulting proof will be undertaken on this manuscript before final publication of the Version of Record (VoR). During production and pre-press, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal relate to this version also. PLEASE SCROLL DOWN FOR ARTICLE Taylor & Francis makes every effort to ensure the accuracy of all the information (the “Content”) contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content. Downloaded by [New York University] at 06:28 19 February 2015 This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions HPV AND CANCER OF THE ORAL CAVITY rip t Christian U. Hübbers1 and Baki Akgül2 1 Jean-Uhrmacher-Institute for Otorhinolaryngological Research, University of Cologne, Geibelstr. 29, 50931 Cologne, an us c 2 Institute of Virology, University of Cologne, Fürst-Pückler-Str. 56, 50935 Cologne, Germany Corresponding author: Dr. Baki Akgül, baki.akguel@uk-koeln.de Key words Abbreviations M Human papillomavirus, Head and neck cancer, oral squamous cell cancer, (human papillomavirus) HNSCC (head and neck squamous cell carcinoma) OPSCC (oropharyngeal squamous cell carcinoma) OSCC (oral squamous cell carcinoma) ep Abstract te d HPV Ac c Downloaded by [New York University] at 06:28 19 February 2015 Germany; Increased awareness of human papillomavirus (HPV) as an etiological cause of head and neck squamous cell carcinoma has increased the interest in analysis of distinct oral sub-sites. It is currently under debate, whether HPV plays a role in the development of squamous cell carcinoma of the oral cavity (OSCC). The weakness in most published studies is the 1 lack of performing different HPV detection tests combined with analysis for biological activity of the virus. In addition, rip t different sub-sites of the oral cavity had been combined to a single entity, which retrospectively leads to a highly an us c M te d ep Ac c Downloaded by [New York University] at 06:28 19 February 2015 heterogeneous basis of data. In this review we mainly discuss the unclear role of HPV in OSCC development. 2 HPV positivity in head and neck cancers rip t Squamous cell carcinoma of the head and neck (HNSCC) is an anatomically heterogeneous group of neoplasms arising from the mucosal surface of the oral cavity, oropharynx, hypopharynx, larynx and nasopharynx. Each year approximately an us c epidemiological work suggests considerable differences between HNSCC related to tumour sub-site. Unfortunately, a shortcoming in many publications is the fact that a simplified grouping of cancers of different head and neck regions as a single entity is retrospectively leading to a highly heterogeneous basis of data. Therefore, important distinctions between 2, 3 . Over the last decade it has become M anatomic sub-sites and their natural histories have not been attributed in detail clear that human papillomaviruses (HPV) not only cause genital and anal cancers, but are also an etiological cause for a te d subset of HNSCC. There are solid indications that incidence and prevalence of HPV-associated HNSCC are increasing which are particularly discussed to be correlated with a decline in smoking habits increased incidence of HPV infections in HNSCC of approximately 50% 6, 7 4, 5 . Recent publications showed an with HPV16 being the most prevalent type in ep at least 90% of this cancer 8. Whereas the majority of HPV-driven cancers of the head and neck are oropharyngeal squamous cell carcinoma (OPSCC) comprising the tonsils and base of the tongue 9, 10 , it is currently in debate whether Ac c Downloaded by [New York University] at 06:28 19 February 2015 263,000 cases of oral cavity cancer and 135,000 cases of pharyngeal cancer are diagnosed worldwide 1. Recent HPV may also have a role in other HNSCC sub-sites. Oncogenic function of HPV HPV is a small DNA virus with a specific tropism for squamous epithelia. To date, 202 different HPV types have been 3 isolated (International HPV Reference Center; (http://ki.se/en/labmed/international-hpv-reference-center) and HPV types rip t infecting the mucosa are further classified into high- and low-risk groups based on the relative malignant potential of the lesions they cause. Whereas low-risk HPVs, such as HPV6 and HPV11, cause benign warts, high-risk HPVs, such as an us c 11, 12 . In a persistent infection the viral E2 protein is tightly controlling the expression of the main viral oncoproteins E6 and E7. These proteins are the key drivers of tumourigenesis by inactivating two of the most important tumour suppressors, pRb and p53 13 . In premalignant and malignant lesions, E2 function gets abrogated, which subsequently leads to higher 14 . The inhibition of the tumour suppressor proteins p53 and pRb alters cell cycle M expression levels of E6 and E7 pathways regulating cellular proliferation, apoptosis, as well as genetic instability, which can lead to the formation of 15 . The binding of high-risk HPV E7 protein with pRb results in the release of the transcription factor E2F te d epithelial lesions from the pRb-E2F protein complex and the promotion of cell cycle progression and also leads to the release of the p16INK4A gene from its transcriptional inhibition. As a consequence, p16INK4A protein is expressed at a high level and is ep thus considered as a reliable surrogate marker for high-risk HPV infection 16. HPV infection of the oral cavity Ac c Downloaded by [New York University] at 06:28 19 February 2015 HPV16 and HPV18, cause premalignant squamous intraepithelial neoplasias that can progress to cancer While HPV is an important cause of OPSCC, it is currently unclear whether HPV may also have a role in other head and neck cancer sub-sites, including oral squamous cell carcinoma (OSCC). A specific role of HPV in the development of OSCC was hypothesized in 1983 and since then is still debated 17-19 . The generally accepted risk factors for cancers of 4 the oral cavity (including tumours of the tongue, floor of the mouth, gingiva, gum, palate, lip mucosa and other sides of the 20 21 , betel quid chewing and alcoholic beverage drinking 22 . The healthy adult population rip t mouth) are tobacco smoking shows a prevalence for any HPV type of 2-8% in the oral cavity, with HPV16 being the most commonly identified type an us c . 25-27, 29 . Furthermore, high-risk sexual behaviour including oral-genital sex has been found to be associated with transmission of HPV infections between oral and genital sites 26, 30, 31 . Immunodeficiency (e.g. HIV infection) and smoking seem to increase the risk for oral HPV infection, i.e. make infections more likely to persist 31 32 . Initial studies suggest that most oral HPV infections are likely to be . Thus, persistence of the virus might be the critical factor for the development of HPV-related M cleared within a year diseases. te d Subclinical and premalignant oral HPV infection In other parts of the body, such as the genital tract, HPV infects exclusively the basal cells of the epithelium, where the ep virus can remain latent. There is evidence that HPV also infects gingival tissue 33, 34 . The periodontal pocket is the only location of the gingival mucosa where basal cells are exposed to the environment. The periodontal pocket enlarges during progression of periodontitis as a result of chronic inflammatory processes Ac c Downloaded by [New York University] at 06:28 19 February 2015 Notably, the prevalence of HPV seems to be significantly higher in men than in women 23-28 35 . In the presence of chronic inflammation, increased basal cell proliferation leads to higher viral load in saliva as well as higher risk of HPV transmission 36 . In a recent hospital-based case-control study with histologically confirmed HNSCC cases, periodontitis was associated with more than 4-fold increased odds of HNSCC. The strength of association was greatest in the oral cavity, followed by 5 oropharynx and larynx 35, 37 . This led to the hypothesis that chronic inflammation and continuous epithelial proliferation in rip t the junctional gingiva could favour the replication of HPV and might be an important reservoir for HPV in the oral mucosa. In (potentially) premalignant oral lesions an increased HPV DNA positivity of 20-64% was described 5, 19, 24, 38-41 . A recent an us c indicating biologically active viral infection, revealed 17.5% positivity for high-risk HPVs in oral epithelial dysplasias (for discussion of p16INK4A immunohistochemistry see below) 42. Does HPV play a causal role in OSCC development? established M In contrast to the clear picture in OPSCC, where the prognostic relevance of biologically active HPV infection is 18, 43, 44 , no such clear association can be found for OSCC. Contradictory studies exist, which are either in 45, 46 , or of worse outcome 47-49 , as well as te d favour of a better survival probability for HPV-positive OSCC patients supporting no effect on patient survival 24, 50, 51. A number of publications analysing larger cohorts underline that HPV DNA and especially HPV16 is present in 10-25% of tumours of the oral cavity, which is higher than in the healthy control 19, 24, 50, 52 ep population but smaller than in OPSCC . In OSCC, HPV16 is followed less frequently by HPV18 (including occasional co-infections with HPV16). Types HPV31, HPV33 and other high-risk types are rarely found 24, 52 . However, in Ac c Downloaded by [New York University] at 06:28 19 February 2015 report by McCord et al. (2013) combining in situ hybridization and immunohistochemical staining against p16INK4A, this respect it should be noted that several studies only tested for selected types namely HPV16 and HPV18 or used more general detection methods not determining the exact type. Beside the general term ‘oral cavity’ used in several studies, it is difficult to estimate the specific prevalence of HPV DNA for the individual sub-sites. Comprehensive studies testing 6 larger numbers of patients (>80) and describing anatomic sub-sites as well as HPV DNA frequency per site indicate that 19, 24, 31, 50, 52-55 (Table 1). Frequencies are varying between studies, but floor of rip t HPV can be found in any of the sub-sites mouth (9-42%) and the tongue (8-25%) seem to be predominantly infected by HPV. Whereas HPV DNA is present in a an us c etiologically HPV-driven 18, 56, 57 . OPSCC are in part truly HPV associated since active high-risk HPV-infection goes along with E6/E7 expression leading to deregulation of especially p53 / pRb and p16INK4A overexpression 14, 58-60 . Beside the fact that HPV DNA can be detected in a subset of OSCC, a series of recent reports presented clear data showing a 50 . Studies analysing expression of E6/E7 in HPV DNA positive M discrepancy in HPV DNA positivity and oncogene activity OSCC could detect expression of viral oncogenes in only 6-7% of cases 50, 52, 61 supporting the assumption that HPV is te d not biologically active in the majority of OSCC. In addition, most HPV-positive OSCC are negative for p16INK4A overexpression and enhanced p16INK4A levels can also be found in HPV-negative tumours. Moreover, there are HPV/p16INK4A positive tumours, in which viral oncogene expression could not be determined 50. Apparently, p16INK4A levels ep might not contribute to decipher active HPV status and other mechanisms controlling p16 INK4A expression in this tumour entity might exist including mutations, deletion or methylation of CDKN2A (gene coding for p16INK4A). Results from the Ac c Downloaded by [New York University] at 06:28 19 February 2015 reasonable subgroup of OSCC, it has been shown that not all of HPV DNA positive tumours can be regarded as cervix uteri show that HPV-driven malignant transformation occurs at a distinct cell population of junctional cells harbouring a unique gene-expression profile that differs from squamous and columnar cells. It is tempting to speculate that similar gene expression profiles also exist at other sites where transition of squamous epithelium into glandular or 7 reticular epithelium occurs (e.g. the oropharynx) and that these conditions influence HPV oncogene expression and rarely rip t promote malignant transformation. Conclusion: an us c entity with many unresolved issues. The lack of a clear molecular evidence raises the question if HPV DNA-positive OSCC are HPV-driven, since the presence of HPV-DNA does not mean the presence of a biologically active HPV per se. In spite of the fact that OSCC is the most common type of oral cancer representing approximately 90% of malignant M tumours in this site, also other tumour entities exist in the oral cavity. Among the non-SCC are adenocarcinoma, adenoid cystic carcinoma from major or minor salivary gland, Kaposi Sarcoma, lymphoma, malignant melanoma and metastatic te d cancers from other head and neck sites 62, 63. As discussed for nasopharyngeal carcinomas, a distinct subset of truly HPVdriven OSCC might have arisen from the oropharynx 24. Further prospective studies focusing on larger collections of welldefined anatomical regions and tumour entities are needed to decipher risk factors for oral cancers. This should include ep exact typing of HPV, detection of viral activity by means of E6/E7 and cellular p16INK4A expression analyses combined with patient survival data. Consequently, these results will provide the basis for the design of future clinical trials. Funding Ac c Downloaded by [New York University] at 06:28 19 February 2015 Several studies showed that HPV DNA is present in a considerable number of OSCC but still represents a distinct clinical The authors would like to thank the Jean-Uhrmacher Foundation for financial support of CUH. 8 References Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: rip t 1. GLOBOCAN 2008. Int J Cancer 2010; 127:2893-917. an us c Rautava J, Syrjanen S. Human papillomavirus infections in the oral mucosa. Journal of the American Dental Association 2011; 142:905-14. 3. Hashibe M, Sturgis EM. Epidemiology of oral-cavity and oropharyngeal carcinomas: controlling a tobacco epidemic while a human papillomavirus epidemic emerges. Otolaryngologic clinics of North America 2013; 46:507-20. Kim L, King T, Agulnik M. Head and neck cancer: changing epidemiology and public health implications. Oncology M 4. 2010; 24:915-9, 24. Jayaprakash V, Reid M, Hatton E, Merzianu M, Rigual N, Marshall J, et al. Human papillomavirus types 16 and 18 te d 5. in epithelial dysplasia of oral cavity and oropharynx: a meta-analysis, 1985-2010. Oral oncology 2011; 47:1048-54. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and - ep 6. unrelated oral squamous cell carcinomas in the United States. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008; 26:612-9. 7. Ac c Downloaded by [New York University] at 06:28 19 February 2015 2. Majchrzak E, Szybiak B, Wegner A, Pienkowski P, Pazdrowski J, Luczewski L, et al. Oral cavity and oropharyngeal squamous cell carcinoma in young adults: a review of the literature. Radiology and oncology 2014; 48:1-10. 8. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell 9 carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005; 14:467-75. D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356:1944-56. an us c Nasman A, Attner P, Hammarstedt L, Du J, Eriksson M, Giraud G, et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer 2009; 125:362-6. 11. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2:342-50. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, et al. The biology and life-cycle of human M 12. papillomaviruses. Vaccine 2012; 30 Suppl 5:F55-70. Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 2010; 10:550-60. Rampias T, Sasaki C, Weinberger P, Psyrri A. E6 and e7 gene silencing and transformed phenotype of human ep 14. te d 13. papillomavirus 16-positive oropharyngeal cancer cells. J Natl Cancer Inst 2009; 101:412-23. 15. Akgül B, Cooke JC, Storey A. HPV-associated skin disease. J Pathol 2006; 208:165-75. 16. von Knebel Doeberitz M. New molecular tools for efficient screening of cervical cancer. Dis Markers 2001; 17:123-8. 17. Syrjänen K, Syrjänen S, Lamberg M, Pyrhonen S, Nuutinen J. Morphological and immunohistochemical evidence Ac c Downloaded by [New York University] at 06:28 19 February 2015 10. rip t 9. suggesting human papillomavirus (HPV) involvement in oral squamous cell carcinogenesis. International journal of oral 10 surgery 1983; 12:418-24. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363:24-35. an us c Syrjänen S, Lodi G, von Bultzingslowen I, Aliko A, Arduino P, Campisi G, et al. Human papillomaviruses in oral carcinoma and oral potentially malignant disorders: a systematic review. Oral diseases 2011; 17 Suppl 1:58-72. IARC. Tobacco Smoke and Involuntary Smoking. Lyon, 2004. 21. IARC. Smokeless Tobacco Products. Lyon, 2007. 22. IARC. Alcohol Drinking. Lyon, 1988. 23. Kreimer AR, Villa A, Nyitray AG, Abrahamsen M, Papenfuss M, Smith D, et al. The epidemiology of oral HPV M 20. 24. te d infection among a multinational sample of healthy men. Cancer Epidemiol Biomarkers Prev 2011; 20:172-82. Isayeva T, Li Y, Maswahu D, Brandwein-Gensler M. Human papillomavirus in non-oropharyngeal head and neck 25. ep cancers: a systematic literature review. Head and neck pathology 2012; 6 Suppl 1:S104-20. Gillison ML, Broutian T, Pickard RK, Tong ZY, Xiao W, Kahle L, et al. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA : the journal of the American Medical Association 2012; 307:693-703. 26. Ac c Downloaded by [New York University] at 06:28 19 February 2015 19. rip t 18. Pickard RK, Xiao W, Broutian TR, He X, Gillison ML. The prevalence and incidence of oral human papillomavirus infection among young men and women, aged 18-30 years. Sexually transmitted diseases 2012; 39:559-66. 27. Bui TC, Markham CM, Ross MW, Mullen PD. Examining the association between oral health and oral HPV 11 infection. Cancer prevention research 2013; 6:917-24. Lang Kuhs KA, Gonzalez P, Struijk L, Castro F, Hildesheim A, van Doorn LJ, et al. Prevalence of and risk factors rip t 28. for oral human papillomavirus among young women in Costa Rica. The Journal of infectious diseases 2013; 208:1643-52. an us c Kero K, Rautava J, Syrjanen K, Grenman S, Syrjanen S. Oral mucosa as a reservoir of human papillomavirus: point prevalence, genotype distribution, and incident infections among males in a 7-year prospective study. European urology 2012; 62:1063-70. 30. D'Souza G, Agrawal Y, Halpern J, Bodison S, Gillison ML. Oral sexual behaviors associated with prevalent oral 31. M human papillomavirus infection. The Journal of infectious diseases 2009; 199:1263-9. Chung CH, Bagheri A, D'Souza G. Epidemiology of oral human papillomavirus infection. Oral oncology 2014; 32. te d 50:364-9. Beachler DC, D'Souza G. Oral human papillomavirus infection and head and neck cancers in HIV-infected 33. ep individuals. Current opinion in oncology 2013; 25:503-10. Madinier I, Doglio A, Cagnon L, Lefebvre JC, Monteil RA. Southern blot detection of human papillomaviruses (HPVs) DNA sequences in gingival tissues. Journal of periodontology 1992; 63:667-73. 34. Ac c Downloaded by [New York University] at 06:28 19 February 2015 29. Hormia M, Willberg J, Ruokonen H, Syrjanen S. Marginal periodontium as a potential reservoir of human papillomavirus in oral mucosa. Journal of periodontology 2005; 76:358-63. 35. Tezal M. Interaction between Chronic Inflammation and Oral HPV Infection in the Etiology of Head and Neck 12 Cancers. International journal of otolaryngology 2012; 2012:575242. Stubenrauch F, Laimins LA. Human papillomavirus life cycle: active and latent phases. Seminars in cancer biology rip t 36. 1999; 9:379-86. an us c Tezal M, Sullivan MA, Hyland A, Marshall JR, Stoler D, Reid ME, et al. Chronic periodontitis and the incidence of head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2009; 18:2406-12. 38. Hafed L, Farag H, Shaker O, El-Rouby D. Is human papilloma virus associated with salivary gland neoplasms? An in situ-hybridization study. Archives of oral biology 2012; 57:1194-9. Kristoffersen AK, Enersen M, Kverndokk E, Sunde PT, Landin M, Solheim T, et al. Human papillomavirus subtypes M 39. in oral lesions compared to healthy oral mucosa. J Clin Virol 2012; 53:364-6. Mattila R, Rautava J, Syrjanen S. Human papillomavirus in oral atrophic lichen planus lesions. Oral oncology 2012; 48:980-4. Mravak-Stipetic M, Sabol I, Kranjcic J, Knezevic M, Grce M. Human papillomavirus in the lesions of the oral ep 41. te d 40. mucosa according to topography. PloS one 2013; 8:e69736. 42. McCord C, Xu J, Xu W, Qiu X, McComb RJ, Perez-Ordonez B, et al. Association of high-risk human papillomavirus Ac c Downloaded by [New York University] at 06:28 19 February 2015 37. infection with oral epithelial dysplasia. Oral surgery, oral medicine, oral pathology and oral radiology 2013; 115:541-9. 43. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92:709-20. 13 44. Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer 45. rip t epidemic. The Lancet Oncology 2010; 11:781-9. Schwartz SR, Yueh B, McDougall JK, Daling JR, Schwartz SM. Human papillomavirus infection and survival in oral an us c 46. Elango KJ, Suresh A, Erode EM, Subhadradevi L, Ravindran HK, Iyer SK, et al. Role of human papilloma virus in oral tongue squamous cell carcinoma. Asian Pacific journal of cancer prevention : APJCP 2011; 12:889-96. 47. Kozomara R, Jovic N, Magic Z, Brankovic-Magic M, Minic V. p53 mutations and human papillomavirus infection in M oral squamous cell carcinomas: correlation with overall survival. Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery 2005; 33:342-8. Duray A, Descamps G, Decaestecker C, Remmelink M, Sirtaine N, Lechien J, et al. Human papillomavirus DNA te d 48. strongly correlates with a poorer prognosis in oral cavity carcinoma. The Laryngoscope 2012; 122:1558-65. Lee LA, Huang CG, Liao CT, Lee LY, Hsueh C, Chen TC, et al. Human papillomavirus-16 infection in advanced ep 49. oral cavity cancer patients is related to an increased risk of distant metastases and poor survival. PloS one 2012; 7:e40767. 50. Ac c Downloaded by [New York University] at 06:28 19 February 2015 squamous cell cancer: a population-based study. Otolaryngol Head Neck Surg 2001; 125:1-9. Reuschenbach M, Kansy K, Garbe K, Vinokurova S, Flechtenmacher C, Toth C, et al. Lack of evidence of human papillomavirus-induced squamous cell carcinomas of the oral cavity in southern Germany. Oral oncology 2013; 49:937-42. 51. Annertz K, Rosenquist K, Andersson G, Jacobsson H, Hansson BG, Wennerberg J. High-risk HPV and survival in 14 patients with oral and oropharyngeal squamous cell carcinoma - 5-year follow up of a population-based study. Acta oto- 52. rip t laryngologica 2014; 134:843-51. Lingen MW, Xiao W, Schmitt A, Jiang B, Pickard R, Kreinbrink P, et al. Low etiologic fraction for high-risk human an us c 53. Duncan LD, Winkler M, Carlson ER, Heidel RE, Kang E, Webb D. p16 immunohistochemistry can be used to detect human papillomavirus in oral cavity squamous cell carcinoma. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 2013; 71:1367-75. Walline HM, Komarck C, McHugh JB, Byrd SA, Spector ME, Hauff SJ, et al. High-risk human papillomavirus M 54. detection in oropharyngeal, nasopharyngeal, and oral cavity cancers: comparison of multiple methods. JAMA 55. te d otolaryngology-- head & neck surgery 2013; 139:1320-7. Upile NS, Shaw RJ, Jones TM, Goodyear P, Liloglou T, Risk JM, et al. Squamous cell carcinoma of the head and 56. ep neck outside the oropharynx is rarely human papillomavirus related. The Laryngoscope 2014. van Houten VM, Snijders PJ, van den Brekel MW, Kummer JA, Meijer CJ, van Leeuwen B, et al. Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell Ac c Downloaded by [New York University] at 06:28 19 February 2015 papillomavirus in oral cavity squamous cell carcinomas. Oral oncology 2013; 49:1-8. carcinomas. Int J Cancer 2001; 93:232-5. 57. Wiest T, Schwarz E, Enders C, Flechtenmacher C, Bosch FX. Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene 2002; 21:1510-7. 15 58. Hoffmann M, Tribius S, Quabius ES, Henry H, Pfannenschmidt S, Burkhardt C, et al. HPV DNA, E6*I-mRNA rip t expression and p16INK4A immunohistochemistry in head and neck cancer - how valid is p16INK4A as surrogate marker? Cancer Lett 2012; 323:88-96. an us c Olthof NC, Straetmans JM, Snoeck R, Ramaekers FC, Kremer B, Speel EJ. Next-generation treatment strategies for human papillomavirus-related head and neck squamous cell carcinoma: where do we go? Rev Med Virol 2012; 22:88105. 60. Olthof NC, Speel EJ, Kolligs J, Haesevoets A, Henfling M, Ramaekers FC, et al. Comprehensive analysis of gene expression. PloS one 2014; 9:e88718. Kouvousi M, Xesfyngi D, Tsimplaki E, Argyri E, Ioannidou G, Ploxorou M, et al. Prevalence of human te d 61. M HPV16 integration in OSCC reveals no significant impact of physical status on viral oncogene and virally disrupted human papillomavirus in 45 greek patients with oral cancer. Journal of oncology 2013; 2013:756510. Daley T, Darling M. Nonsquamous cell malignant tumours of the oral cavity: an overview. Journal 2003; 69:577-82. 63. Shiiba M, Unozawa M, Higo M, Kouzu Y, Kasamatsu A, Sakamoto Y, et al. Controlling distant metastasis and ep 62. surgical treatment are crucial for improving clinical outcome in uncommon head and neck malignancies, such as non- Ac c Downloaded by [New York University] at 06:28 19 February 2015 59. squamous cell carcinoma. Molecular and clinical oncology 2014; 2:609-17. 16 Syrjänen 2011 Review 1885 Isayeva et al., 2012 Review 4195 Durray et al., 2012 Research article 162 Duncan et al., 2013 Research article 81 HPV detection methods rip t OSCC subsites and sitespecific HPVpositivity Overall HPV DNA positivity Concordanc e between HPV DNA positivity and other methods $ Cancers of other sites tested WP = 20.2%; 95% CI 16.0% 25.2% $ larynx, sinonasal tract, nasopharynx 44% No No 8.6% Yes No OR = 3.98; 95% CI: 2.62 - 6.02 Lip mucosa (66.7%) Palate (33.3%) Floor of mouth (24.0%) Tongue (23.2%) Retromolar trigone (16.7%) Cheek (14.3%) Gums (14.3%) Jawbone (0%) Buccal mucosa (25.0%) Floor of the mouth (9.1%) Tongue (8.3%) Gingiva (7.7%) Hard palate (0%) Lip mucosa (0%) an us c No. of OSCC GP5+ / GP6+ PCR, type specific INK4A E6/E7 PCR, P16 / p53 / EGFR IHC, ISH No M Article type te d Reference PCR, p16 INK4A IHC ep Ac c Downloaded by [New York University] at 06:28 19 February 2015 Table 1:Studies analysing cohorts > 80 OSCC patients by use of independend HPV detection methods. 17 Research article 275 89 n.d. 5.9%; 95% CI 3.6 - 8.2 No No rip t Reuschenbach et al., 2013 SPF10 PCR, TaqMan qRT-PCR, ISH INK4A p16 IHC an us c 104 Floor of mouth (37.5%) Tongue (25.0%) Alveolar process (16.7%) Hard palate (12.5%) Gingiva (4.2%) Lip mucosa (4.2%) Buccal mucosa (0%) Retromolar trigone (0%) Vestibule of mouth (0%) Floor of mouth (42.0%) Tongue (23.2%) Mandibula r alveole (18.8%) Lip mucosa (7.2%) Buccal mucosa (5.8%) Maxillar alveole (2.9%) n.d. M 409 PCR-EIA, ISH INK4A p16 IHC 25.1% No No 9.6% No Oropharynx, Nasopharynx 14.6% No Hypopharynx, Larynx ep te d Research article Ac c Downloaded by [New York University] at 06:28 19 February 2015 Lingen et al., 2013 Walline et al., 2013 Chung et al., 2014 Research article Research article PCR Mass-array, ISH, p16 IHC INK4A p16 IHC, ISH INK4A 18 Floor of mouth (n.d.) Buccal mucosa (n.d.) Alveolar process (n.d.) Oral tongue (n.d.) Retromolar trigone (n.d.) p16 INK4A IHC, ISH, HPV16-E6 Qpcr 4% No Oropharynx, Larynx, Hypopharynx rip t 102 an us c Research article ep te d M WP = weighted prevalence, OR = odds ratio; CI = confidence interval ISH = in situ hybridization, IHC = Immunohistochemistry, EIA= enzyme linked immuno assay EGFR: epidermal growth factor receptor n.d. = not described Ac c Downloaded by [New York University] at 06:28 19 February 2015 Upile et al., 2014 19